Analysis of lung cancer measures of the National Cancer Network pilot study in Poland for potential improvement in the quality of advanced-stage lung cancer therapy

Abstract Background This study aimed to present the performance of the National Cancer Network’s (NCN) pilot program in the Lower Silesian Voivodeship (southwestern province of Poland with a population of 2,9 million in 2019), to analyse measures describing lung cancer patients and to determine whet...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Łukasz Trembecki, Aleksandra Sztuder, Ireneusz Pawlak, Rafał Matkowski, Adam Maciejczyk
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Lung cancer Quality measures Targeted therapy Poland Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a2d27439b7544412a2401318779e9faa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a2d27439b7544412a2401318779e9faa
record_format	dspace
spelling	oai:doaj.org-article:a2d27439b7544412a2401318779e9faa2021-11-21T12:30:38ZAnalysis of lung cancer measures of the National Cancer Network pilot study in Poland for potential improvement in the quality of advanced-stage lung cancer therapy10.1186/s12885-021-08994-z1471-2407https://doaj.org/article/a2d27439b7544412a2401318779e9faa2021-11-01T00:00:00Zhttps://doi.org/10.1186/s12885-021-08994-zhttps://doaj.org/toc/1471-2407Abstract Background This study aimed to present the performance of the National Cancer Network’s (NCN) pilot program in the Lower Silesian Voivodeship (southwestern province of Poland with a population of 2,9 million in 2019), to analyse measures describing lung cancer patients and to determine whether those measures can be used to improve the treatment outcomes of stage III and IV patients with lung cancer in Poland. Methods Three measures of the NCN pilot programme were analysed: “Percentage of patients with genetic and molecular testing for predictive factors”, “Assessment of the completeness of a pathological examination”, and “Percentage of stage III and IV cancer patients”. As many as 2,218 patients with ICD-10-CM Diagnosis Code C34 were included in the NCN pilot program from 1 to 2019 to 31 December 2020, in the Lower Silesian Voivodeship. The scores of each measure were calculated quarterly by the Regional Coordinating Centre, Wroclaw Comprehensive Cancer Center, Wroclaw, Poland. Results Genetic and molecular testing among stage III and IV patients was performed in only 40% and 60% of patients, respectively. The incompleteness of histopathological examinations did not exceed 0.5%. Stage III and stage IV patients accounted for 37% and 35% of the analysed patients, respectively. Conclusions The NCN pilot program measures presented in this study appear to be highly sensitive, simple, and transparent tools to monitor the quality of lung cancer diagnosis and assess clinical staging in patients within a specific region. An increase in the proportion of stage III and IV patients who will undergo genetic and molecular testing in the era of modern drug therapies should result in improved treatment outcomes in this patient group. In the present analysis, the values of the main analysed measure, which evaluates the number of genetic and molecular tests for predictive factors for lung cancer, were subject to significant fluctuations during the pilot project. Both upwards and downwards trends were observed. Further analysis in the future is warranted to eliminate the unfavourable factors influencing the obtained values of the measure.Łukasz TrembeckiAleksandra SztuderIreneusz PawlakRafał MatkowskiAdam MaciejczykBMCarticleLung cancerQuality measuresTargeted therapyPolandNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Lung cancer Quality measures Targeted therapy Poland Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Lung cancer Quality measures Targeted therapy Poland Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Łukasz Trembecki Aleksandra Sztuder Ireneusz Pawlak Rafał Matkowski Adam Maciejczyk Analysis of lung cancer measures of the National Cancer Network pilot study in Poland for potential improvement in the quality of advanced-stage lung cancer therapy
description	Abstract Background This study aimed to present the performance of the National Cancer Network’s (NCN) pilot program in the Lower Silesian Voivodeship (southwestern province of Poland with a population of 2,9 million in 2019), to analyse measures describing lung cancer patients and to determine whether those measures can be used to improve the treatment outcomes of stage III and IV patients with lung cancer in Poland. Methods Three measures of the NCN pilot programme were analysed: “Percentage of patients with genetic and molecular testing for predictive factors”, “Assessment of the completeness of a pathological examination”, and “Percentage of stage III and IV cancer patients”. As many as 2,218 patients with ICD-10-CM Diagnosis Code C34 were included in the NCN pilot program from 1 to 2019 to 31 December 2020, in the Lower Silesian Voivodeship. The scores of each measure were calculated quarterly by the Regional Coordinating Centre, Wroclaw Comprehensive Cancer Center, Wroclaw, Poland. Results Genetic and molecular testing among stage III and IV patients was performed in only 40% and 60% of patients, respectively. The incompleteness of histopathological examinations did not exceed 0.5%. Stage III and stage IV patients accounted for 37% and 35% of the analysed patients, respectively. Conclusions The NCN pilot program measures presented in this study appear to be highly sensitive, simple, and transparent tools to monitor the quality of lung cancer diagnosis and assess clinical staging in patients within a specific region. An increase in the proportion of stage III and IV patients who will undergo genetic and molecular testing in the era of modern drug therapies should result in improved treatment outcomes in this patient group. In the present analysis, the values of the main analysed measure, which evaluates the number of genetic and molecular tests for predictive factors for lung cancer, were subject to significant fluctuations during the pilot project. Both upwards and downwards trends were observed. Further analysis in the future is warranted to eliminate the unfavourable factors influencing the obtained values of the measure.
format	article
author	Łukasz Trembecki Aleksandra Sztuder Ireneusz Pawlak Rafał Matkowski Adam Maciejczyk
author_facet	Łukasz Trembecki Aleksandra Sztuder Ireneusz Pawlak Rafał Matkowski Adam Maciejczyk
author_sort	Łukasz Trembecki
title	Analysis of lung cancer measures of the National Cancer Network pilot study in Poland for potential improvement in the quality of advanced-stage lung cancer therapy
title_short	Analysis of lung cancer measures of the National Cancer Network pilot study in Poland for potential improvement in the quality of advanced-stage lung cancer therapy
title_full	Analysis of lung cancer measures of the National Cancer Network pilot study in Poland for potential improvement in the quality of advanced-stage lung cancer therapy
title_fullStr	Analysis of lung cancer measures of the National Cancer Network pilot study in Poland for potential improvement in the quality of advanced-stage lung cancer therapy
title_full_unstemmed	Analysis of lung cancer measures of the National Cancer Network pilot study in Poland for potential improvement in the quality of advanced-stage lung cancer therapy
title_sort	analysis of lung cancer measures of the national cancer network pilot study in poland for potential improvement in the quality of advanced-stage lung cancer therapy
publisher	BMC
publishDate	2021
url	https://doaj.org/article/a2d27439b7544412a2401318779e9faa
work_keys_str_mv	AT łukasztrembecki analysisoflungcancermeasuresofthenationalcancernetworkpilotstudyinpolandforpotentialimprovementinthequalityofadvancedstagelungcancertherapy AT aleksandrasztuder analysisoflungcancermeasuresofthenationalcancernetworkpilotstudyinpolandforpotentialimprovementinthequalityofadvancedstagelungcancertherapy AT ireneuszpawlak analysisoflungcancermeasuresofthenationalcancernetworkpilotstudyinpolandforpotentialimprovementinthequalityofadvancedstagelungcancertherapy AT rafałmatkowski analysisoflungcancermeasuresofthenationalcancernetworkpilotstudyinpolandforpotentialimprovementinthequalityofadvancedstagelungcancertherapy AT adammaciejczyk analysisoflungcancermeasuresofthenationalcancernetworkpilotstudyinpolandforpotentialimprovementinthequalityofadvancedstagelungcancertherapy
_version_	1718418961201102848

Analysis of lung cancer measures of the National Cancer Network pilot study in Poland for potential improvement in the quality of advanced-stage lung cancer therapy

Ejemplares similares